It has been previously demonstrated that combining the Ad5 cancer vaccine (encoding a model TSA) with intratumoral administration of the adjuvant cytosine guanine oligonucleotide (CpG ODN) significantly reduces tumor growth and increases survival in mice, along with increasing the proportion of antigen-specific CD8+ T cells in the TME and peripheral blood (15, 22). Here, CD8A is linked to cancer.